William Yashar

  • Current Program Year: Grad2
  • Current Student, Biomedical Engineering Graduate Program, School of Medicine
  • M.D./Ph.D. Program Students, School of Medicine


Research Interests: Computational biology, leukemogenesis, epigenetics, treatment resistance, intratumoral heterogeneity

Education and training

    • B.S., 2015, Massachusetts Institute of Technology


Selected publications

  • Lu SM, Scanderbeg DJ, Barna P, Yashar W, Yashar C. Evaluation of two intracavitary high-dose-rate brachytherapy devices for irradiating additional and irregularly shaped volumes of breast tissue. Med Dosim. 2012 Spring;37(1):9-14. doi: 10.1016/j.meddos.2010.12.005. Epub 2011 Apr 1. PMID: 21458981.
  • Strik AS, Wang YC, Ruff LE, Yashar W, Messmer BT, Mould DR. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm? AAPS J. 2018 Sep 5;20(6):99. doi: 10.1208/s12248-018-0257-y. PMID: 30187153; PMCID: PMC8364290.
  • PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Brittany M. Smith, Jake VanCampen, Garth L. Kong, William Yashar, Wesley Horton, Daniel J. Coleman, Joseph Estabrook, Theresa A. Lusardi, Brain J. Druker, Julia E. Maxson, Theodore P. Braun. bioRxiv 2021.08.24.456354; doi: https://doi


  • {{ pub.journalAssociation.journal.name.text[0].value }}